FAQ

NKTR-118

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2015
01220102015

Related topics

Related topics

1 relation

Broader (1)

naloxegol

Related mentions per year

Related mentions per year

2010-2018
201020122014201620182020
NKTR-118
naloxegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The role of naloxegol in the management of opioid-induced bowel dysfunction.
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD… (More)
Is this relevant?
2015
2015
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
This randomized, double-blind, placebo-controlled, ascending-dose, crossover study evaluated single oral doses of naloxegol (NKTR… (More)
Is this relevant?
2015
2015
Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Opioid-induced constipation (OIC) is the most common and often a treatment-limiting adverse event (AE) of opioid therapy for… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
2013
2013
A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
Naloxegol (previously known as NKTR-118) is a peripherally acting μ-opioid receptor antagonist engineered using polymer conjugate… (More)
Is this relevant?
Review
2011
Review
2011
Novel opioid antagonists for opioid-induced bowel dysfunction.
INTRODUCTION Adverse effects frequently limit the therapeutic benefits of opioid analgesics. Gastrointestinal adverse effects are… (More)
  • table 1
Is this relevant?
Review
2011
Review
2011
Opioid-Induced Constipation: Challenges and Therapeutic Opportunities
There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years… (More)
Is this relevant?
Review
2011
Review
2011
Interval Signet-Ring Cell Adenocarcinoma of the Colon: Missed or De Novo?
INTRODUCTION Th ere has been an alarming increase in the prescription and chronic use of opiates and opioids for chronic non… (More)
  • table 1
  • figure 1
Is this relevant?
2010
2010
28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.
The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing… (More)
Is this relevant?